NEW YORK, May 2, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on four major players in the Drug Manufacturers space: Novartis AG (NYSE: NVS), TherapeuticsMD Inc. (NYSE MKT: TXMD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), and Retrophin Inc. (NASDAQ: RTRX). Drug manufacturers develop and sell medicines and vaccines for a wide range of medical uses, and many of them offer slightly higher-than-average dividend yields. You can access our complimentary research reports on these stocks now at:
Shares in Basel, Switzerland headquartered Novartis AG saw a slight drop of 0.04%, ending Monday's trading session at $77.00. The stock recorded a trading volume of 1.24 million shares. The Company's shares have gained 3.00% in the last one month, 10.38% over the previous three months, and 9.56% on an YTD basis. The stock is trading 3.09% and 4.68% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have a Relative Strength Index (RSI) of 68.43. Visit us today and download your complete report on NVS for free at:
On Monday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. recorded a trading volume of 3.23 million shares, which was higher than their three months average volume of 3.05 million shares. The stock ended the day 1.76% lower at $5.01. The Company's shares are trading below their 50-day moving average by 20.39%. Furthermore, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 34.04.
On April 19th, 2017, TherapeuticsMD announced that, based on continued correspondence with the US Food and Drug Administration (FDA), the Company expects that the latter will finalize an action on the New Drug Application (NDA) for TX-004HR, an investigational bio-identical 17β-estradiol vaginal softgel capsule for the treatment of dyspareunia, and inform the Company of the deficiencies in the NDA identified, on or before the originally scheduled Prescription Drug User Fee Act target action date of May 07th, 2017. The complimentary research report on TXMD can be accessed at:
New York-based Tonix Pharmaceuticals Holding Corp.'s stock rose 4.78%, closing the day at $4.38 with a total trading volume of 227,815 shares. The Company's shares have surged 672.49% in the previous three months and 831.72% since the start of this year. The stock is trading 59.47% and 209.28% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Tonix Pharma, which develops medicines for common disorders of the central nervous system, have an RSI of 61.50.
On April 17th, 2017, Tonix Pharma announced financial results for Q4 and full year ended December 31st, 2016. The Company reported net losses of $7.5 million and $38.8 million for Q4 and the full year 2016, respectively. In addition, cash used in operations was $37.3 million for the year ended December 31st, 2016. Register for free on Stock-Callers.com and download the PDF research report on TNXP at:
San Diego, California headquartered Retrophin Inc.'s stock declined 0.71%, finishing yesterday's session at $19.45 with a total trading volume of 222,071 shares. The Company's shares have advanced 7.82% in the last one month, 4.63% in the previous three months, and 2.75% on an YTD basis. The stock is trading above its 50-day moving average by 1.83%. Additionally, shares of Retrophin, which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases, have an RSI of 55.66.
On April 20th, 2017, Retrophin announced that it will report Q1 2017 financial results on Thursday, May 04th, 2017, after the close of the US financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss its financial results and provide a general business update. The live webcast may be accessed under the "Investors" page of the Company's website. Get free access to your research report on RTRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA